1Q22 Business Results

Key Business Performance YuflymaⓇ / CT-P16 ✓ YuflymaⓇ, the only low volume & citrate-free Adalimumab biosimilar, started to enter European market in 2022 in earnest ✓ Aiming to launch CT-P16(AvastinⓇ biosimilar) within a year in the US, Europe, and Japan which accounts for 80% of the Bevacizumab market Market size of Adalimumab in EU Global Market size of Bevacizumab 100% 3% 5% 15% 75% 16% 13% 50% 19% EU 42% Adalimumab Market Size $5.0bn 58% 25% 42% ■Low concentration High concentration Note: market size is as of 2021 Source: IQVIA 0% ■HumiraⓇ ■ImraldiⓇ ■ Hulio® AmgevitaⓇ ■HyrimozⓇ Idacio® 15% 24% Global Bevacizumab Market Size $6.0bn 48% ■ US ■ Europe Japan ■ROW Note: market size is as of 2021 Source: IQVIA Investor Relations 2022 12

View entire presentation